摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-N-[2-Chloro-3-(4-acetylpiperazin-1-yl)-4-(isopropylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide | 329926-36-5

中文名称
——
中文别名
——
英文名称
(R)-N-[2-Chloro-3-(4-acetylpiperazin-1-yl)-4-(isopropylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide
英文别名
(R)-N-[2-chloro-3-(1-(4-acetyl)piperazinyl)-4-(isopropylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide;(2R)-N-[3-(4-acetylpiperazin-1-yl)-2-chloro-4-propan-2-ylsulfonylphenyl]-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide
(R)-N-[2-Chloro-3-(4-acetylpiperazin-1-yl)-4-(isopropylsulphonyl)phenyl]-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide化学式
CAS
329926-36-5
化学式
C19H25ClF3N3O5S
mdl
——
分子量
499.939
InChiKey
GPKJFSJOBJNXDQ-GOSISDBHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    32
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    115
  • 氢给体数:
    2
  • 氢受体数:
    9

文献信息

  • SUBSTITUTED N-PHENYL 2-HYDROXY-2-METHYL-3,3,3-TRIFLUOROPROPANAMIDE DERIVATIVES WHICH ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY
    申请人:AstraZeneca AB
    公开号:EP1214296B1
    公开(公告)日:2004-03-24
  • US6689909B1
    申请人:——
    公开号:US6689909B1
    公开(公告)日:2004-02-10
  • [EN] SUBSTITUTED N-PHENYL 2-HYDROXY-2-METHYL-3,3,3-TRIFLUOROPROPANAMIDE DERIVATIVES WHICH ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY<br/>[FR] DERIVES DE N-PHENYL 2-HYDROXY-2-METHYL-3,3,3-TRIFLUOROPROPANAMIDE SUBSTITUES DESTINES A AUGMENTER L'ACTIVITE DE PYRUVATE DESHYDROGENASE
    申请人:ASTRAZENECA AB
    公开号:WO2001017956A1
    公开(公告)日:2001-03-15
    A compound of formula (I) wherein: n is 1 or 2; R1 is chloro, fluoro, bromo, methyl or methoxy; R2 is as defined within; R3 is as defined within; and R4 is hydrogen or fluoro; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof is described. The use of compounds of formula (I) in the production of an elevation of PDH activity in a warm-blooded animal such as a human being are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.
查看更多